One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation

INTRODUCTION[|]This study was a comparison of the results achieved in patients with age-related macular degeneration and retinal angiomatous proliferation (RAP) diagnosis receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy and receiving photodynamic treatment (PDT)...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Cem Kesim [verfasserIn] Ali Demircan [verfasserIn] Zeynep Alkin [verfasserIn] Korhan Fazil [verfasserIn] Abdullah Ozkaya [verfasserIn] Muhittin Taskapili [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2017

Schlagwörter:	anti-vascular endothelial growth factor photodynamic treatment retinal angiomatous proliferation.

Übergeordnetes Werk:	In: Beyoglu Eye Journal - KARE Publishing, 2020, 2(2017), 2, Seite 62-63
Übergeordnetes Werk:	volume:2 ; year:2017 ; number:2 ; pages:62-63

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.14744/bej.2017.46036

Katalog-ID:	DOAJ056029268

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ056029268
003	DE-627
005	20230310183648.0
007	cr uuu---uuuuu
008	230227s2017 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.14744/bej.2017.46036 \|2 doi
035			\|a (DE-627)DOAJ056029268
035			\|a (DE-599)DOAJeb677a5c28f743b3b100e11fd3da866d
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RE1-994
100	0		\|a Cem Kesim \|e verfasserin \|4 aut
245	1	0	\|a One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation
264		1	\|c 2017
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a INTRODUCTION[\|]This study was a comparison of the results achieved in patients with age-related macular degeneration and retinal angiomatous proliferation (RAP) diagnosis receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy and receiving photodynamic treatment (PDT) combined with anti-VEGF treatment.[¤]METHODS[\|]A retrospective chart review of patients with RAP who were treated in the retina clinic of Beyoglu Eye Training and Research Hospital was conducted. Patients were divided into 2 groups: patients who received anti-VEGF monotherapy formed Group I, and Group II comprised those who underwent combined therapy with PDT. Best corrected visual acuity (BCVA) and central macular thickness values at baseline and at months 6 and 12, and the number of anti-VEGF injections and PDT sessions were recorded.[¤]RESULTS[\|]Fifteen eyes of 14 patients were included. Six of the patients were female and 8 were male; the mean age was 73.2+-9.7 years. The mean baseline BCVA was 0.70+-0.52 log of the minimum angle of resolution. Visual acuity increased in 1 of 15 eyes (6.6%), remained stable in 10 eyes (66.6%), and decreased in 4 eyes (26.6%). A total of 7 eyes received anti-VEGF monotherapy, and 8 eyes received combined PDT and anti-VEGF treatment. The mean number of injections was 10.7+-7.8. Five eyes received 1 PDT session and 3 eyes received 2 sessions.[¤]DISCUSSION AND CONCLUSION[\|]In this study, visual acuity was preserved in the majority of patients receiving anti-VEGF monotherapy and combined PDT and anti-VEGF treatment for RAP lesions.[¤]
650		4	\|a anti-vascular endothelial growth factor
650		4	\|a photodynamic treatment
650		4	\|a retinal angiomatous proliferation.
653		0	\|a Ophthalmology
700	0		\|a Ali Demircan \|e verfasserin \|4 aut
700	0		\|a Zeynep Alkin \|e verfasserin \|4 aut
700	0		\|a Korhan Fazil \|e verfasserin \|4 aut
700	0		\|a Abdullah Ozkaya \|e verfasserin \|4 aut
700	0		\|a Muhittin Taskapili \|e verfasserin \|4 aut
773	0	8	\|i In \|t Beyoglu Eye Journal \|d KARE Publishing, 2020 \|g 2(2017), 2, Seite 62-63 \|w (DE-627)1725122200 \|x 25870394 \|7 nnns
773	1	8	\|g volume:2 \|g year:2017 \|g number:2 \|g pages:62-63
856	4	0	\|u https://doi.org/10.14744/bej.2017.46036 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/eb677a5c28f743b3b100e11fd3da866d \|z kostenfrei
856	4	0	\|u https://jag.journalagent.com/z4/download_fulltext.asp?pdir=beyoglu&un=BEJ-46036 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2587-0394 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 2 \|j 2017 \|e 2 \|h 62-63

Indexfelder

author_variant	c k ck a d ad z a za k f kf a o ao m t mt
matchkey_str	article:25870394:2017----::nyaotoecmaiooatvgmnteayncmieatvgpooyaiteayo
hierarchy_sort_str	2017
callnumber-subject-code	RE
publishDate	2017
allfields	10.14744/bej.2017.46036 doi (DE-627)DOAJ056029268 (DE-599)DOAJeb677a5c28f743b3b100e11fd3da866d DE-627 ger DE-627 rakwb eng RE1-994 Cem Kesim verfasserin aut One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUCTION[\|]This study was a comparison of the results achieved in patients with age-related macular degeneration and retinal angiomatous proliferation (RAP) diagnosis receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy and receiving photodynamic treatment (PDT) combined with anti-VEGF treatment.[¤]METHODS[\|]A retrospective chart review of patients with RAP who were treated in the retina clinic of Beyoglu Eye Training and Research Hospital was conducted. Patients were divided into 2 groups: patients who received anti-VEGF monotherapy formed Group I, and Group II comprised those who underwent combined therapy with PDT. Best corrected visual acuity (BCVA) and central macular thickness values at baseline and at months 6 and 12, and the number of anti-VEGF injections and PDT sessions were recorded.[¤]RESULTS[\|]Fifteen eyes of 14 patients were included. Six of the patients were female and 8 were male; the mean age was 73.2+-9.7 years. The mean baseline BCVA was 0.70+-0.52 log of the minimum angle of resolution. Visual acuity increased in 1 of 15 eyes (6.6%), remained stable in 10 eyes (66.6%), and decreased in 4 eyes (26.6%). A total of 7 eyes received anti-VEGF monotherapy, and 8 eyes received combined PDT and anti-VEGF treatment. The mean number of injections was 10.7+-7.8. Five eyes received 1 PDT session and 3 eyes received 2 sessions.[¤]DISCUSSION AND CONCLUSION[\|]In this study, visual acuity was preserved in the majority of patients receiving anti-VEGF monotherapy and combined PDT and anti-VEGF treatment for RAP lesions.[¤] anti-vascular endothelial growth factor photodynamic treatment retinal angiomatous proliferation. Ophthalmology Ali Demircan verfasserin aut Zeynep Alkin verfasserin aut Korhan Fazil verfasserin aut Abdullah Ozkaya verfasserin aut Muhittin Taskapili verfasserin aut In Beyoglu Eye Journal KARE Publishing, 2020 2(2017), 2, Seite 62-63 (DE-627)1725122200 25870394 nnns volume:2 year:2017 number:2 pages:62-63 https://doi.org/10.14744/bej.2017.46036 kostenfrei https://doaj.org/article/eb677a5c28f743b3b100e11fd3da866d kostenfrei https://jag.journalagent.com/z4/download_fulltext.asp?pdir=beyoglu&un=BEJ-46036 kostenfrei https://doaj.org/toc/2587-0394 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2017 2 62-63
spelling	10.14744/bej.2017.46036 doi (DE-627)DOAJ056029268 (DE-599)DOAJeb677a5c28f743b3b100e11fd3da866d DE-627 ger DE-627 rakwb eng RE1-994 Cem Kesim verfasserin aut One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUCTION[\|]This study was a comparison of the results achieved in patients with age-related macular degeneration and retinal angiomatous proliferation (RAP) diagnosis receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy and receiving photodynamic treatment (PDT) combined with anti-VEGF treatment.[¤]METHODS[\|]A retrospective chart review of patients with RAP who were treated in the retina clinic of Beyoglu Eye Training and Research Hospital was conducted. Patients were divided into 2 groups: patients who received anti-VEGF monotherapy formed Group I, and Group II comprised those who underwent combined therapy with PDT. Best corrected visual acuity (BCVA) and central macular thickness values at baseline and at months 6 and 12, and the number of anti-VEGF injections and PDT sessions were recorded.[¤]RESULTS[\|]Fifteen eyes of 14 patients were included. Six of the patients were female and 8 were male; the mean age was 73.2+-9.7 years. The mean baseline BCVA was 0.70+-0.52 log of the minimum angle of resolution. Visual acuity increased in 1 of 15 eyes (6.6%), remained stable in 10 eyes (66.6%), and decreased in 4 eyes (26.6%). A total of 7 eyes received anti-VEGF monotherapy, and 8 eyes received combined PDT and anti-VEGF treatment. The mean number of injections was 10.7+-7.8. Five eyes received 1 PDT session and 3 eyes received 2 sessions.[¤]DISCUSSION AND CONCLUSION[\|]In this study, visual acuity was preserved in the majority of patients receiving anti-VEGF monotherapy and combined PDT and anti-VEGF treatment for RAP lesions.[¤] anti-vascular endothelial growth factor photodynamic treatment retinal angiomatous proliferation. Ophthalmology Ali Demircan verfasserin aut Zeynep Alkin verfasserin aut Korhan Fazil verfasserin aut Abdullah Ozkaya verfasserin aut Muhittin Taskapili verfasserin aut In Beyoglu Eye Journal KARE Publishing, 2020 2(2017), 2, Seite 62-63 (DE-627)1725122200 25870394 nnns volume:2 year:2017 number:2 pages:62-63 https://doi.org/10.14744/bej.2017.46036 kostenfrei https://doaj.org/article/eb677a5c28f743b3b100e11fd3da866d kostenfrei https://jag.journalagent.com/z4/download_fulltext.asp?pdir=beyoglu&un=BEJ-46036 kostenfrei https://doaj.org/toc/2587-0394 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2017 2 62-63
allfields_unstemmed	10.14744/bej.2017.46036 doi (DE-627)DOAJ056029268 (DE-599)DOAJeb677a5c28f743b3b100e11fd3da866d DE-627 ger DE-627 rakwb eng RE1-994 Cem Kesim verfasserin aut One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUCTION[\|]This study was a comparison of the results achieved in patients with age-related macular degeneration and retinal angiomatous proliferation (RAP) diagnosis receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy and receiving photodynamic treatment (PDT) combined with anti-VEGF treatment.[¤]METHODS[\|]A retrospective chart review of patients with RAP who were treated in the retina clinic of Beyoglu Eye Training and Research Hospital was conducted. Patients were divided into 2 groups: patients who received anti-VEGF monotherapy formed Group I, and Group II comprised those who underwent combined therapy with PDT. Best corrected visual acuity (BCVA) and central macular thickness values at baseline and at months 6 and 12, and the number of anti-VEGF injections and PDT sessions were recorded.[¤]RESULTS[\|]Fifteen eyes of 14 patients were included. Six of the patients were female and 8 were male; the mean age was 73.2+-9.7 years. The mean baseline BCVA was 0.70+-0.52 log of the minimum angle of resolution. Visual acuity increased in 1 of 15 eyes (6.6%), remained stable in 10 eyes (66.6%), and decreased in 4 eyes (26.6%). A total of 7 eyes received anti-VEGF monotherapy, and 8 eyes received combined PDT and anti-VEGF treatment. The mean number of injections was 10.7+-7.8. Five eyes received 1 PDT session and 3 eyes received 2 sessions.[¤]DISCUSSION AND CONCLUSION[\|]In this study, visual acuity was preserved in the majority of patients receiving anti-VEGF monotherapy and combined PDT and anti-VEGF treatment for RAP lesions.[¤] anti-vascular endothelial growth factor photodynamic treatment retinal angiomatous proliferation. Ophthalmology Ali Demircan verfasserin aut Zeynep Alkin verfasserin aut Korhan Fazil verfasserin aut Abdullah Ozkaya verfasserin aut Muhittin Taskapili verfasserin aut In Beyoglu Eye Journal KARE Publishing, 2020 2(2017), 2, Seite 62-63 (DE-627)1725122200 25870394 nnns volume:2 year:2017 number:2 pages:62-63 https://doi.org/10.14744/bej.2017.46036 kostenfrei https://doaj.org/article/eb677a5c28f743b3b100e11fd3da866d kostenfrei https://jag.journalagent.com/z4/download_fulltext.asp?pdir=beyoglu&un=BEJ-46036 kostenfrei https://doaj.org/toc/2587-0394 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2017 2 62-63
allfieldsGer	10.14744/bej.2017.46036 doi (DE-627)DOAJ056029268 (DE-599)DOAJeb677a5c28f743b3b100e11fd3da866d DE-627 ger DE-627 rakwb eng RE1-994 Cem Kesim verfasserin aut One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUCTION[\|]This study was a comparison of the results achieved in patients with age-related macular degeneration and retinal angiomatous proliferation (RAP) diagnosis receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy and receiving photodynamic treatment (PDT) combined with anti-VEGF treatment.[¤]METHODS[\|]A retrospective chart review of patients with RAP who were treated in the retina clinic of Beyoglu Eye Training and Research Hospital was conducted. Patients were divided into 2 groups: patients who received anti-VEGF monotherapy formed Group I, and Group II comprised those who underwent combined therapy with PDT. Best corrected visual acuity (BCVA) and central macular thickness values at baseline and at months 6 and 12, and the number of anti-VEGF injections and PDT sessions were recorded.[¤]RESULTS[\|]Fifteen eyes of 14 patients were included. Six of the patients were female and 8 were male; the mean age was 73.2+-9.7 years. The mean baseline BCVA was 0.70+-0.52 log of the minimum angle of resolution. Visual acuity increased in 1 of 15 eyes (6.6%), remained stable in 10 eyes (66.6%), and decreased in 4 eyes (26.6%). A total of 7 eyes received anti-VEGF monotherapy, and 8 eyes received combined PDT and anti-VEGF treatment. The mean number of injections was 10.7+-7.8. Five eyes received 1 PDT session and 3 eyes received 2 sessions.[¤]DISCUSSION AND CONCLUSION[\|]In this study, visual acuity was preserved in the majority of patients receiving anti-VEGF monotherapy and combined PDT and anti-VEGF treatment for RAP lesions.[¤] anti-vascular endothelial growth factor photodynamic treatment retinal angiomatous proliferation. Ophthalmology Ali Demircan verfasserin aut Zeynep Alkin verfasserin aut Korhan Fazil verfasserin aut Abdullah Ozkaya verfasserin aut Muhittin Taskapili verfasserin aut In Beyoglu Eye Journal KARE Publishing, 2020 2(2017), 2, Seite 62-63 (DE-627)1725122200 25870394 nnns volume:2 year:2017 number:2 pages:62-63 https://doi.org/10.14744/bej.2017.46036 kostenfrei https://doaj.org/article/eb677a5c28f743b3b100e11fd3da866d kostenfrei https://jag.journalagent.com/z4/download_fulltext.asp?pdir=beyoglu&un=BEJ-46036 kostenfrei https://doaj.org/toc/2587-0394 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2017 2 62-63
allfieldsSound	10.14744/bej.2017.46036 doi (DE-627)DOAJ056029268 (DE-599)DOAJeb677a5c28f743b3b100e11fd3da866d DE-627 ger DE-627 rakwb eng RE1-994 Cem Kesim verfasserin aut One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUCTION[\|]This study was a comparison of the results achieved in patients with age-related macular degeneration and retinal angiomatous proliferation (RAP) diagnosis receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy and receiving photodynamic treatment (PDT) combined with anti-VEGF treatment.[¤]METHODS[\|]A retrospective chart review of patients with RAP who were treated in the retina clinic of Beyoglu Eye Training and Research Hospital was conducted. Patients were divided into 2 groups: patients who received anti-VEGF monotherapy formed Group I, and Group II comprised those who underwent combined therapy with PDT. Best corrected visual acuity (BCVA) and central macular thickness values at baseline and at months 6 and 12, and the number of anti-VEGF injections and PDT sessions were recorded.[¤]RESULTS[\|]Fifteen eyes of 14 patients were included. Six of the patients were female and 8 were male; the mean age was 73.2+-9.7 years. The mean baseline BCVA was 0.70+-0.52 log of the minimum angle of resolution. Visual acuity increased in 1 of 15 eyes (6.6%), remained stable in 10 eyes (66.6%), and decreased in 4 eyes (26.6%). A total of 7 eyes received anti-VEGF monotherapy, and 8 eyes received combined PDT and anti-VEGF treatment. The mean number of injections was 10.7+-7.8. Five eyes received 1 PDT session and 3 eyes received 2 sessions.[¤]DISCUSSION AND CONCLUSION[\|]In this study, visual acuity was preserved in the majority of patients receiving anti-VEGF monotherapy and combined PDT and anti-VEGF treatment for RAP lesions.[¤] anti-vascular endothelial growth factor photodynamic treatment retinal angiomatous proliferation. Ophthalmology Ali Demircan verfasserin aut Zeynep Alkin verfasserin aut Korhan Fazil verfasserin aut Abdullah Ozkaya verfasserin aut Muhittin Taskapili verfasserin aut In Beyoglu Eye Journal KARE Publishing, 2020 2(2017), 2, Seite 62-63 (DE-627)1725122200 25870394 nnns volume:2 year:2017 number:2 pages:62-63 https://doi.org/10.14744/bej.2017.46036 kostenfrei https://doaj.org/article/eb677a5c28f743b3b100e11fd3da866d kostenfrei https://jag.journalagent.com/z4/download_fulltext.asp?pdir=beyoglu&un=BEJ-46036 kostenfrei https://doaj.org/toc/2587-0394 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2017 2 62-63
language	English
source	In Beyoglu Eye Journal 2(2017), 2, Seite 62-63 volume:2 year:2017 number:2 pages:62-63
sourceStr	In Beyoglu Eye Journal 2(2017), 2, Seite 62-63 volume:2 year:2017 number:2 pages:62-63
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	anti-vascular endothelial growth factor photodynamic treatment retinal angiomatous proliferation. Ophthalmology
isfreeaccess_bool	true
container_title	Beyoglu Eye Journal
authorswithroles_txt_mv	Cem Kesim @@aut@@ Ali Demircan @@aut@@ Zeynep Alkin @@aut@@ Korhan Fazil @@aut@@ Abdullah Ozkaya @@aut@@ Muhittin Taskapili @@aut@@
publishDateDaySort_date	2017-01-01T00:00:00Z
hierarchy_top_id	1725122200
id	DOAJ056029268
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ056029268</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310183648.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2017 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14744/bej.2017.46036</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ056029268</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJeb677a5c28f743b3b100e11fd3da866d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RE1-994</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Cem Kesim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">INTRODUCTION[\|]This study was a comparison of the results achieved in patients with age-related macular degeneration and retinal angiomatous proliferation (RAP) diagnosis receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy and receiving photodynamic treatment (PDT) combined with anti-VEGF treatment.[¤]METHODS[\|]A retrospective chart review of patients with RAP who were treated in the retina clinic of Beyoglu Eye Training and Research Hospital was conducted. Patients were divided into 2 groups: patients who received anti-VEGF monotherapy formed Group I, and Group II comprised those who underwent combined therapy with PDT. Best corrected visual acuity (BCVA) and central macular thickness values at baseline and at months 6 and 12, and the number of anti-VEGF injections and PDT sessions were recorded.[¤]RESULTS[\|]Fifteen eyes of 14 patients were included. Six of the patients were female and 8 were male; the mean age was 73.2+-9.7 years. The mean baseline BCVA was 0.70+-0.52 log of the minimum angle of resolution. Visual acuity increased in 1 of 15 eyes (6.6%), remained stable in 10 eyes (66.6%), and decreased in 4 eyes (26.6%). A total of 7 eyes received anti-VEGF monotherapy, and 8 eyes received combined PDT and anti-VEGF treatment. The mean number of injections was 10.7+-7.8. Five eyes received 1 PDT session and 3 eyes received 2 sessions.[¤]DISCUSSION AND CONCLUSION[\|]In this study, visual acuity was preserved in the majority of patients receiving anti-VEGF monotherapy and combined PDT and anti-VEGF treatment for RAP lesions.[¤]</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anti-vascular endothelial growth factor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">photodynamic treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">retinal angiomatous proliferation.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Ophthalmology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ali Demircan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zeynep Alkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Korhan Fazil</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Abdullah Ozkaya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Muhittin Taskapili</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Beyoglu Eye Journal</subfield><subfield code="d">KARE Publishing, 2020</subfield><subfield code="g">2(2017), 2, Seite 62-63</subfield><subfield code="w">(DE-627)1725122200</subfield><subfield code="x">25870394</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:62-63</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14744/bej.2017.46036</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/eb677a5c28f743b3b100e11fd3da866d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://jag.journalagent.com/z4/download_fulltext.asp?pdir=beyoglu&un=BEJ-46036</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2587-0394</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">62-63</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Cem Kesim
spellingShingle	Cem Kesim misc RE1-994 misc anti-vascular endothelial growth factor misc photodynamic treatment misc retinal angiomatous proliferation. misc Ophthalmology One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation
authorStr	Cem Kesim
ppnlink_with_tag_str_mv	@@773@@(DE-627)1725122200
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RE1-994
illustrated	Not Illustrated
issn	25870394
topic_title	RE1-994 One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation anti-vascular endothelial growth factor photodynamic treatment retinal angiomatous proliferation
topic	misc RE1-994 misc anti-vascular endothelial growth factor misc photodynamic treatment misc retinal angiomatous proliferation. misc Ophthalmology
topic_unstemmed	misc RE1-994 misc anti-vascular endothelial growth factor misc photodynamic treatment misc retinal angiomatous proliferation. misc Ophthalmology
topic_browse	misc RE1-994 misc anti-vascular endothelial growth factor misc photodynamic treatment misc retinal angiomatous proliferation. misc Ophthalmology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Beyoglu Eye Journal
hierarchy_parent_id	1725122200
hierarchy_top_title	Beyoglu Eye Journal
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1725122200
title	One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation
ctrlnum	(DE-627)DOAJ056029268 (DE-599)DOAJeb677a5c28f743b3b100e11fd3da866d
title_full	One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation
author_sort	Cem Kesim
journal	Beyoglu Eye Journal
journalStr	Beyoglu Eye Journal
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2017
contenttype_str_mv	txt
container_start_page	62
author_browse	Cem Kesim Ali Demircan Zeynep Alkin Korhan Fazil Abdullah Ozkaya Muhittin Taskapili
container_volume	2
class	RE1-994
format_se	Elektronische Aufsätze
author-letter	Cem Kesim
doi_str_mv	10.14744/bej.2017.46036
author2-role	verfasserin
title_sort	one-year outcomes comparison of anti-vegf monotherapy and combined anti-vegf+photodynamic therapy for retinal angiomatous proliferation
callnumber	RE1-994
title_auth	One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation
abstract	INTRODUCTION[\|]This study was a comparison of the results achieved in patients with age-related macular degeneration and retinal angiomatous proliferation (RAP) diagnosis receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy and receiving photodynamic treatment (PDT) combined with anti-VEGF treatment.[¤]METHODS[\|]A retrospective chart review of patients with RAP who were treated in the retina clinic of Beyoglu Eye Training and Research Hospital was conducted. Patients were divided into 2 groups: patients who received anti-VEGF monotherapy formed Group I, and Group II comprised those who underwent combined therapy with PDT. Best corrected visual acuity (BCVA) and central macular thickness values at baseline and at months 6 and 12, and the number of anti-VEGF injections and PDT sessions were recorded.[¤]RESULTS[\|]Fifteen eyes of 14 patients were included. Six of the patients were female and 8 were male; the mean age was 73.2+-9.7 years. The mean baseline BCVA was 0.70+-0.52 log of the minimum angle of resolution. Visual acuity increased in 1 of 15 eyes (6.6%), remained stable in 10 eyes (66.6%), and decreased in 4 eyes (26.6%). A total of 7 eyes received anti-VEGF monotherapy, and 8 eyes received combined PDT and anti-VEGF treatment. The mean number of injections was 10.7+-7.8. Five eyes received 1 PDT session and 3 eyes received 2 sessions.[¤]DISCUSSION AND CONCLUSION[\|]In this study, visual acuity was preserved in the majority of patients receiving anti-VEGF monotherapy and combined PDT and anti-VEGF treatment for RAP lesions.[¤]
abstractGer	INTRODUCTION[\|]This study was a comparison of the results achieved in patients with age-related macular degeneration and retinal angiomatous proliferation (RAP) diagnosis receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy and receiving photodynamic treatment (PDT) combined with anti-VEGF treatment.[¤]METHODS[\|]A retrospective chart review of patients with RAP who were treated in the retina clinic of Beyoglu Eye Training and Research Hospital was conducted. Patients were divided into 2 groups: patients who received anti-VEGF monotherapy formed Group I, and Group II comprised those who underwent combined therapy with PDT. Best corrected visual acuity (BCVA) and central macular thickness values at baseline and at months 6 and 12, and the number of anti-VEGF injections and PDT sessions were recorded.[¤]RESULTS[\|]Fifteen eyes of 14 patients were included. Six of the patients were female and 8 were male; the mean age was 73.2+-9.7 years. The mean baseline BCVA was 0.70+-0.52 log of the minimum angle of resolution. Visual acuity increased in 1 of 15 eyes (6.6%), remained stable in 10 eyes (66.6%), and decreased in 4 eyes (26.6%). A total of 7 eyes received anti-VEGF monotherapy, and 8 eyes received combined PDT and anti-VEGF treatment. The mean number of injections was 10.7+-7.8. Five eyes received 1 PDT session and 3 eyes received 2 sessions.[¤]DISCUSSION AND CONCLUSION[\|]In this study, visual acuity was preserved in the majority of patients receiving anti-VEGF monotherapy and combined PDT and anti-VEGF treatment for RAP lesions.[¤]
abstract_unstemmed	INTRODUCTION[\|]This study was a comparison of the results achieved in patients with age-related macular degeneration and retinal angiomatous proliferation (RAP) diagnosis receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy and receiving photodynamic treatment (PDT) combined with anti-VEGF treatment.[¤]METHODS[\|]A retrospective chart review of patients with RAP who were treated in the retina clinic of Beyoglu Eye Training and Research Hospital was conducted. Patients were divided into 2 groups: patients who received anti-VEGF monotherapy formed Group I, and Group II comprised those who underwent combined therapy with PDT. Best corrected visual acuity (BCVA) and central macular thickness values at baseline and at months 6 and 12, and the number of anti-VEGF injections and PDT sessions were recorded.[¤]RESULTS[\|]Fifteen eyes of 14 patients were included. Six of the patients were female and 8 were male; the mean age was 73.2+-9.7 years. The mean baseline BCVA was 0.70+-0.52 log of the minimum angle of resolution. Visual acuity increased in 1 of 15 eyes (6.6%), remained stable in 10 eyes (66.6%), and decreased in 4 eyes (26.6%). A total of 7 eyes received anti-VEGF monotherapy, and 8 eyes received combined PDT and anti-VEGF treatment. The mean number of injections was 10.7+-7.8. Five eyes received 1 PDT session and 3 eyes received 2 sessions.[¤]DISCUSSION AND CONCLUSION[\|]In this study, visual acuity was preserved in the majority of patients receiving anti-VEGF monotherapy and combined PDT and anti-VEGF treatment for RAP lesions.[¤]
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation
url	https://doi.org/10.14744/bej.2017.46036 https://doaj.org/article/eb677a5c28f743b3b100e11fd3da866d https://jag.journalagent.com/z4/download_fulltext.asp?pdir=beyoglu&un=BEJ-46036 https://doaj.org/toc/2587-0394
remote_bool	true
author2	Ali Demircan Zeynep Alkin Korhan Fazil Abdullah Ozkaya Muhittin Taskapili
author2Str	Ali Demircan Zeynep Alkin Korhan Fazil Abdullah Ozkaya Muhittin Taskapili
ppnlink	1725122200
callnumber-subject	RE - Ophthalmology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.14744/bej.2017.46036
callnumber-a	RE1-994
up_date	2024-07-03T18:27:42.702Z
_version_	1803583501319012352
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ056029268</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310183648.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2017 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14744/bej.2017.46036</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ056029268</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJeb677a5c28f743b3b100e11fd3da866d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RE1-994</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Cem Kesim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">INTRODUCTION[\|]This study was a comparison of the results achieved in patients with age-related macular degeneration and retinal angiomatous proliferation (RAP) diagnosis receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy and receiving photodynamic treatment (PDT) combined with anti-VEGF treatment.[¤]METHODS[\|]A retrospective chart review of patients with RAP who were treated in the retina clinic of Beyoglu Eye Training and Research Hospital was conducted. Patients were divided into 2 groups: patients who received anti-VEGF monotherapy formed Group I, and Group II comprised those who underwent combined therapy with PDT. Best corrected visual acuity (BCVA) and central macular thickness values at baseline and at months 6 and 12, and the number of anti-VEGF injections and PDT sessions were recorded.[¤]RESULTS[\|]Fifteen eyes of 14 patients were included. Six of the patients were female and 8 were male; the mean age was 73.2+-9.7 years. The mean baseline BCVA was 0.70+-0.52 log of the minimum angle of resolution. Visual acuity increased in 1 of 15 eyes (6.6%), remained stable in 10 eyes (66.6%), and decreased in 4 eyes (26.6%). A total of 7 eyes received anti-VEGF monotherapy, and 8 eyes received combined PDT and anti-VEGF treatment. The mean number of injections was 10.7+-7.8. Five eyes received 1 PDT session and 3 eyes received 2 sessions.[¤]DISCUSSION AND CONCLUSION[\|]In this study, visual acuity was preserved in the majority of patients receiving anti-VEGF monotherapy and combined PDT and anti-VEGF treatment for RAP lesions.[¤]</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anti-vascular endothelial growth factor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">photodynamic treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">retinal angiomatous proliferation.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Ophthalmology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ali Demircan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zeynep Alkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Korhan Fazil</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Abdullah Ozkaya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Muhittin Taskapili</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Beyoglu Eye Journal</subfield><subfield code="d">KARE Publishing, 2020</subfield><subfield code="g">2(2017), 2, Seite 62-63</subfield><subfield code="w">(DE-627)1725122200</subfield><subfield code="x">25870394</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:62-63</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14744/bej.2017.46036</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/eb677a5c28f743b3b100e11fd3da866d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://jag.journalagent.com/z4/download_fulltext.asp?pdir=beyoglu&un=BEJ-46036</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2587-0394</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">62-63</subfield></datafield></record></collection>
score	7.39758

Nicht das Richtige dabei?

Schreiben Sie uns!

One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?